Clomicalm® (clomipramine hydrochloride)

CLOMICALM tablets:

• Along with behavior modification, may help alleviate inappropriate barking and elimination (urination or defecation), as well as destructive behavior
• Although they may cause lethargy in some dogs, their mode of action is not as a sedative
• Have been trusted for more than 17 years

Indications:

CLOMICALM Tablets are to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age. Inappropriate barking or destructive behavior, as well as inappropriate elimination (urination or defecation) may be alleviated by the use of CLOMICALM Tablets in conjunction with behavior modification.

Dosage and Administration:

The recommended daily dose of CLOMICALM Tablets is 2 to 4 mg/kg/day (0.9 -1.8 mg/lb/day) (see dosing table below). It can be administered as a single daily dose or divided twice daily based on patient response and/or tolerance of the side effects.

It may be prudent to initiate treatment in divided doses to minimize side effects by permitting tolerance to side effects to develop or allowing the patient time to adapt if tolerance does not develop. To reduce the incidence of vomiting that may be experienced by some dogs, CLOMICALM Tablets may be given with a small amount of food.

Important Safety Information:

Do not use in dogs with known hypersensitivity to clomipramine or other tricyclic antidepressants, or in breeding male dogs, dogs less than 6 months of age, dogs with a history of seizures, or concomitantly with drugs which lower the seizure threshold. Do not give within 14 days before or after treatment with a monoamine oxidase inhibitor. 

Not for use in humans. Keep out of reach of children. In case of accidental ingestion, which can have serious consequences, seek medical help immediately. There is no specific antidote for clomipramine. People with known hypersensitivity to clomipramine should administer the product with caution. 

• Not recommended for behavior problems such as aggression.
• Other causes of inappropriate behavior unrelated to separation anxiety should be ruled out before prescribing.
• Caution is advised with concomitant use of anticholinergic or sympathomimetic drugs or other CNS-active drugs.
• Use with caution in dogs with cardiovascular disease, increased intraocular pressure, a history of narrow angle glaucoma, urinary retention or reduced gastrointestinal motility and preexisting liver disease.

Safety has not been established in pregnant or lactating female dogs. The most common adverse reactions reported in field studies were emesis, lethargy and diarrhea.